SGMT - NASDAQ

Sagimet Biosciences Inc.

SGMT·NASDAQ

$6.86

+1.3%

HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$223.51M

EPS-1.5800

P/E Ratio-4.34

Earnings Date08/12/2026

sgmt

Net Common Stock Issuance

Last Annual Value

275.00K

3-Year CAGR

184%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Sagimet Biosciences Inc. Competitors Analysis of Net Common Stock Issuance

SGMT · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Sagimet Biosciences Inc. NASDAQ:SGMT	275.00K	-85.5%	N/A	N/A
Voyager Therapeutics, Inc. NASDAQ:VYGR	816.00K	-71.1%	5.9%	N/A
Atea Pharmaceuticals, Inc. NASDAQ:AVIR	-25.26M	N/A	N/A	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	174.67M	133.7%	27.0%	102.2%
Humacyte, Inc. NASDAQ:HUMA	113.44M	485.2%	N/A	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	4.82M	-68.4%	-56.8%	N/A
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA	145.00K	-59.7%	-47.4%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	86.82M	57.5%	57.3%	N/A
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT	13.38M	180.1%	91.8%	N/A
Foghorn Therapeutics Inc. NASDAQ:FHTX	1.02M	N/A	-52.5%	N/A
Zura Bio Limited NASDAQ:ZURA	5.20M	-64.5%	-48.3%	N/A

Sagimet Biosciences Inc. Fair Value Envelope

SGMT · NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.86, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

HIDDEN

Intrinsic Value

Current Price: $6.86

Related Guides

Blog Categories

Continue your SGMT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.